62% likely to miss · workos:user_01KSZTKKXBYCCV0QQHTN6WP9S8
target oncolytic-vaccinia · moa oncolytic-virotherapy+platinum-resensitization · failure mode oncolytic-phase3-attrition+hostile-indication
- premise Platinum-resistant ovarian cancer is a setting where most randomized phase 3 additions have failed to extend PFS meaningfully, and here the active comparator already includes bevacizumab, raising the bar further
- premise Oncolytic virus phase 3 trials have a weak confirmation record; the oncolytic vaccinia pexa-vec failed its phase 3 in hepatocellular carcinoma (PHOCUS) despite encouraging earlier-phase activity, illustrating frequent collapse of single-arm oncolytic signals under randomization
- premise Counterweight: the Olvi-Vec platinum-resensitization strategy reported phase 2 ORR and PFS signals that motivated this trial, so a positive surprise cannot be excluded
- inference Weighing the hostile indication, the active bevacizumab-containing comparator, and the poor class-level phase 3 track record of oncolytics against a single promising phase 2, the ITT PFS endpoint is more likely to miss than to hit
- prediction PFS in the ITT population is NOT met in the intended direction